Efficacy of Autologous Bone Marrow-Derived Mesenchymal Stem Cell and Mononuclear Cell Transplantation in Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Comparative Study

2017 ◽  
Vol 26 (7) ◽  
pp. 471-481 ◽  
Author(s):  
Shobhit Bhansali ◽  
Pinaki Dutta ◽  
Vinod Kumar ◽  
Mukesh Kumar Yadav ◽  
Ashish Jain ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bone Marrow ◽  
Type 2 Diabetes Mellitus ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Comparative Study ◽  
Autologous Bone Marrow ◽  
Autologous Bone

Efficacy of Autologous Bone Marrow–Derived Stem Cell Transplantation in Patients With Type 2 Diabetes Mellitus

2009 ◽  
Vol 18 (10) ◽  
pp. 1407-1416 ◽  
Author(s):  
Anil Bhansali ◽  
Vimal Upreti ◽  
N. Khandelwal ◽  
N. Marwaha ◽  
Vivek Gupta ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bone Marrow ◽  
Type 2 Diabetes Mellitus ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Bone Marrow ◽  
Autologous Bone

scholarly journals CORRECTION: A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report

2019 ◽  
Vol 6 (4) ◽  
pp. 3140
Author(s):  
Phuong Thi-Bich Le ◽  
Nguyen Phu-Van Doan ◽  
Phan Van Tien ◽  
Dang Ngo Chau Hoang ◽  
Ngoc Kim Phan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bone Marrow ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Autologous Bone Marrow ◽  
Diabetes Mellitus Patient ◽  
Autologous Bone

In the previous publication with title ”A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report”1, page 2968, in the Table 1, the unit for fasting blood glucose and blood glucose 2 hours after meals is mg/dL; however, the corrected unit for fasting blood glucose and blood glucose 2 hours after meal is mmol/L.  

scholarly journals A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report

2019 ◽  
Vol 6 (1) ◽  
pp. 2966-2969 ◽  
Author(s):  
Phuong Thi-Bich Le ◽  
Nguyen Phu-Van Doan ◽  
Phan Van Tien ◽  
Dang Ngo Chau Hoang ◽  
Ngoc Kim Phan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bone Marrow ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Bone Marrow ◽  
Insulin Injection ◽  
Autologous Bone

Introduction: Type 2 diabetes mellitus (T2DM) iscurrently one of the most common diseases as a result of obesity and aging. Currently, T2DMis treated by various methods, such as insulin injection and glucose regulation agents. In this report, we report the case of a T2DM patient who was successfully treated by autologous bone marrow-derived stem cell transplantation. Methods: The patient was diagnosed with T2DM by standard methods for more than ten years. The patient agreed to be treated by the new approach – autologous bone marrow-derived stem cell transplantation. The bone marrow was collected from the patient twice at 100 mL volume each time. The stem cellenriched mononuclear cells (MNCs) in the bone marrow were isolated by gradient centrifugation. MNCs were intravenously transfused into the patient twice within the 1-month interval. The lasting glucose and 2h-after meal glucose, as well as hemoglobin A1c (Hab1c), were recorded before transplantation, and 1-, 3-, and 6-months post-transplantation. Results: The results showed that there were no adverse effect recorded during the monitoring period, and that the T2DM symptoms significantly improved. After the first round of transplantation, the glucose level reduced considerably and continued to decrease out to 3 months. Meanwhile, after 2 months of transplantation, the Hab1C level decreased and achieved the average level at the 3rd month of treatment. After 6 months, the patient was free from insulin injection and maintained glucose and Hab1c level. To date, after 9 months of treatment; the patients has continued to be free from insulin injection and without any adverse effects. Conclusion: The primary results have suggested that autologous bone marrow-derived stem cell transplantation may be a new direction for T2DM treatment.  

Biodistribution of 18F-FDG-Labeled Autologous Bone Marrow–Derived Stem Cells in Patients With Type 2 Diabetes Mellitus

2015 ◽  
Vol 40 (9) ◽  
pp. 697-700 ◽  
Author(s):  
Vikas Sood ◽  
Bhagwant R. Mittal ◽  
Anil Bhansali ◽  
Baljinder Singh ◽  
Niranjan Khandelwal ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Bone Marrow ◽  
Type 2 Diabetes Mellitus ◽  
Autologous Bone Marrow ◽  
Autologous Bone ◽  
18F Fdg

Combined Treatment of Intrapancreatic Autologous Bone Marrow Stem Cells and Hyperbaric Oxygen in Type 2 Diabetes Mellitus

2008 ◽  
Vol 17 (12) ◽  
pp. 1295-1304 ◽  
Author(s):  
Esteban J. Estrada ◽  
Fabian Valacchi ◽  
Eduardo Nicora ◽  
Sergio Brieva ◽  
Claudio Esteve ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Bone Marrow ◽  
Type 2 Diabetes Mellitus ◽  
Hyperbaric Oxygen ◽  
Combined Treatment ◽  
Autologous Bone Marrow ◽  
Autologous Bone
Sign in / Sign up

Export Citation Format

Share Document